Influenza virus is a viral pathogen of significant medical importance causing severe morbidity and mortality every year around the world, and which remains ever in the background as a pandemic threat. Available prophylactic vaccines are not completely effective against emerging strains and the currently available anti-influenza drugs have experienced limited efficacy.

InfluMedix is a privately held biopharmaceutical company dedicated to discovering and developing novel therapeutics for the treatment of seasonal and pandemic influenza (including 2009 H1N1 pandemic flu and avian H5N1 flu).